文献速递血栓与止血

癌症相关孤立性远端深静脉血栓患者的临床表现与结局

Clinical Presentation and Outcomes of Patients With Cancer-Associated Isolated Distal Deep Vein Thrombosis.
PubMed 文献 · J Clin Oncol · 2023-07-20

基于国际注册研究,比较886例癌症相关远端深静脉血栓(DVT)与5196例癌症相关近端DVT及5974例非癌症相关远端DVT患者90天和1年的不良结局风险。癌症相关远端DVT的死亡、VTE复发或大出血风险显著高于非癌症相关远端DVT,但与癌症相关近端DVT相比无统计学差异;近端DVT致命性肺栓塞风险更高(风险差0.40%)。

要点

  • 癌症相关远端DVT的死亡、VTE复发及大出血风险显著高于非癌症相关远端DVT
  • 癌症相关远端DVT与近端DVT在90天和1年的不良结局风险无统计学差异
  • 癌症相关近端DVT较远端DVT致命性肺栓塞风险更高,风险差0.40%

核心结论

  • 癌症相关远端DVT具有严重且与近端DVT相对可比的结局。
  • 癌症相关远端DVT致命性肺栓塞风险较低,需进一步研究。

研究设计与样本

  • 利用国际Registro Informatizado de la Enfermedad TromboEmbolica venosa注册研究数据,比较886例癌症相关远端DVT与5196例癌症相关近端DVT及5974例非癌症相关远端DVT患者。
  • 每组超过90%的患者接受抗凝治疗至少90天。
  • 比较90天不良结局的风险(调整比值比[aOR];95%CI)和1年不良结局的风险(调整风险比[aHR;95%CI])。

主要发现

  • 90天时,非癌症相关远端DVT患者相比癌症相关远端DVT(参照组)的死亡风险aOR=0.16(0.11-0.22),VTE复发风险aOR=0.34(0.22-0.54),大出血风险aOR=0.47(0.27-0.80)。
  • 1年随访时结果相似:非癌症相关远端DVT相比癌症相关远端DVT的死亡风险aHR=0.12(0.09-0.15),VTE复发风险aHR=0.39(0.28-0.55),大出血风险aHR=0.51(0.32-0.82)。
  • 90天时,癌症相关近端DVT与远端DVT相比,死亡风险aOR=1.11(0.91-1.36),VTE复发风险aOR=1.10(0.76-1.62),大出血风险aOR=1.18(0.76-1.83),均无统计学差异。
  • 1年时,癌症相关近端DVT与远端DVT相比,死亡风险aHR=1.01(0.89-1.15),VTE复发风险aHR=1.02(0.76-1.35),大出血风险aHR=1.10(0.76-1.61),均无统计学差异。
  • 随访期间,癌症相关近端DVT患者较远端DVT患者更多发生致命性肺栓塞,风险差为0.40%(95%CI,0.23至0.58)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with isolated distal deep vein thrombosis (DVT) have lower rates of adverse outcomes (death, venous thromboembolism [VTE] recurrence or major bleeding) than those with proximal DVT. It is uncertain if such findings are also observed in patients with cancer. METHODS: Using data from the international Registro Informatizado de la Enfermedad TromboEmbolica venosa registry, we compared the risks of adverse outcomes at 90 days (adjusted odds ratio [aOR]; 95% CI) and 1 year (adjusted hazard ratio [aHR; 95% CI]) in 886 patients with cancer-associated distal DVT versus 5,196 patients with cancer-associated proximal DVT and 5,974 patients with non-cancer-associated distal DVT. RESULTS: More than 90% of patients in each group were treated with anticoagulants for at least 90 days. At 90 days, the adjusted risks of death, VTE recurrence, or major bleeding were lower in patients with non-cancer-associated distal DVT than in patients with cancer-associated distal DVT (reference): aOR = 0.16 (0.11-0.22), aOR = 0.34 (0.22-0.54), and aOR = 0.47 (0.27-0.80), respectively. The results were similar at 1-year follow-up: aHR = 0.12 (0.09-0.15), aHR = 0.39 (0.28-0.55), and aHR = 0.51 (0.32-0.82), respectively. Risks of death, VTE recurrence, and major bleeding were not statistically different between patients with cancer-associated proximal versus distal DVT, both at 90 days: aOR = 1.11 (0.91-1.36), aOR = 1.10 (0.76-1.62), and aOR = 1.18 (0.76-1.83), respectively, and 1 year: aHR = 1.01 (0.89-1.15), aHR = 1.02 (0.76-1.35), and aHR = 1.10 (0.76-1.61), respectively. However, more patients with cancer-associated proximal DVT, compared with cancer-associated distal DVT, developed fatal pulmonary embolism (PE) during follow-up: The risk difference was 0.40% (95% CI, 0.23 to 0.58). CONCLUSION: Cancer-associated distal DVT has serious and relatively comparable outcomes compared with cancer-associated proximal DVT. The lower risk of fatal PE from cancer-associated distal DVT needs further investigation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Galanaud JP, Trujillo-Santos J, Bikdeli B, et al. Clinical Presentation and Outcomes of Patients With Cancer-Associated Isolated Distal Deep Vein Thrombosis. J Clin Oncol. 2023. PMID: 37471683. doi:10.1200/JCO.23.00429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。